← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Operational Technologies Corporation
San Antonio, TX
$2,069,783
Total funding
9
Grants
Funding over time
peak $534.5K · FY2009–17$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$1,869,860 · 7
NSF$199,923 · 2
By mechanism
R44$999,469 · 1
N43$523,310 · 3
R43$347,081 · 3
—$199,923 · 2
Investigators at Operational Technologies Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Anti-OLAM Aptamers as Novel Analgesics (Phase 2)$534,504
R44 · FY2015 · GM
Development of Anti-OLAM Aptamers as Novel Analgesics (Phase 2)$464,965
R44 · FY2016 · GM
Proof of concept investigation to detect exposure of patients to Cytomegalovirus (CMV) and Herpes Simplex Virus-2 (HSV-2)$223,323
N43 · FY2017 · AI
TOPIC 319 TECHNOLOGY TO GENERATE ANTI PEPTIDE CAPTUE REAGENTS FOR AFFINITY ENRIFH$199,996
N43 · FY2013 · CA
Development of Anti-OLAM Aptamers as Novel Analgesics$147,234
R43 · FY2012 · GM
TAS::75 0872::TAS DNA APTAMERS FOR CARDIOVASCULAR RESEARCH$99,991
N43 · FY2010 · HL
SBIR Phase I: FRET-Aptamer Tests for Treated Wastewater$99,990
· FY2009 · TIP
Nuclease-Resistant Aptamers for Anthrax Opsonization$99,934
R43 · FY2004 · AI
SBIR Phase I: Nuclease-Shielded DNA Aptamer Antibiotics that Couple with Complement$99,933
· FY2003 · TIP
Nuclease-Resistant Aptamers to Botox and Anthrax Toxins$99,913
R43 · FY2004 · AI